



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/926,322	10/15/2001	Piero Del Soldato	108907-00019	5288

4372 7590 08/01/2005
ARENT FOX PLLC
1050 CONNECTICUT AVENUE, N.W.
SUITE 400
WASHINGTON, DC 20036

EXAMINER

BADIO, BARBARA P

ART UNIT PAPER NUMBER

1617

DATE MAILED: 08/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Response to Rule 312 Communication	Application No.	Applicant(s)	
	09/926,322	DEL SOLDATO, PIERO	
	Examiner	Art Unit	
	Barbara P. Badio, Ph.D.	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☐ The amendment filed on 06 July 2005 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.


c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☒ entered in part. See explanation below.

An amendment to claim 11 was made by Examiner's Amendment (see Examiner's Amendment attached hereto).


 Barbara P. Badio, Ph.D.
 Primary Examiner
 Art Unit: 1617

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Gautam Prakash on July 26, 2005.

The application has been amended as follows:

Claim 11 has been rewritten as follows: --

Claim 11. Compounds or their salts having the following general formula (I):



wherein:





A = R-T₁, wherein:

R is the radical of a drug having formula R-T₁-H or R-T₁-OH selected from the group of anti-inflammatory drugs consisting of acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olosalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid; tolfeamic acid, tolmetin, zomepirac, and tomoxiprol;


Art Unit: 1617

 $T_1 = (\text{CO})$ or X wherein: $X = \text{O}, \text{S}, \text{N}, \text{NR}_{1\text{C}}$ wherein: $R_{1\text{C}}$ is H or a linear or branched $\text{C}_1\text{-C}_5$ alkyl; $\text{B} = -\text{T}_\text{B}-\text{X}_2-\text{T}_{\text{B}1}-$ wherein: T_B and $\text{T}_{\text{B}1}$ are equal or different, and $\text{T}_\text{B} = (\text{CO})$ when T_1 is X , $\text{T}_\text{B} = X$ when T_1 is (CO) , X being as above defined; $\text{T}_{\text{B}1} = (\text{CO})$ or X , X being as above defined,

X_2 is a bivalent bridging group between T_B and $\text{T}_{\text{B}1}$, wherein $-\text{T}_\text{B}-\text{X}_2-\text{T}_{\text{B}1}-$ is selected from the group consisting of



and



and

 $\text{T}_\text{C} = (\text{CO})$ when $\text{T}_{\text{B}1}$ is X , or $\text{T}_\text{C} = X$ when $\text{T}_{\text{B}1}$ is (CO) , X being as above defined, Y is $Y_0 =$ an alkyleneoxy group $\text{R}'\text{O}$ wherein R' is linear or branched C_1 to C_{20} alkyl.

--


Art Unit: 1617

Telephone Inquiry

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara P. Badio, Ph.D. whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Barbara P. Badio, Ph.D.
Primary Examiner
Art Unit 1617

BB

July 26, 2005